Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. (Q45810988)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

0 references

1 reference

Maria Rosaria Anna Muscatello

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Antonio Bruno

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Gianluca Pandolfo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

U Micò

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

P M Bellinghieri

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

G Scimeca

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

M Cacciola

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

D Campolo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

S Settineri

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

R Zoccali

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

English

0 references

publication date

8 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

Journal of Psychopharmacology

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

667-674

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20615930%20AND%20SRC:MED&resulttype=core&format=json

Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Symptoms of schizophrenia. Methods, meanings, and mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Review of the use of Topiramate for treatment of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

21 January 2018

Dissociative Anesthesia

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Topiramate antagonizes MK-801 in an animal model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

A revised excitotoxic hypothesis of schizophrenia: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Glycine agonists: what can they teach us about schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Antiepileptic drugs in schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Effects of Topiramate on Aggressive, Self-Injurious, and Disruptive/Destructive Behaviors in the Intellectually Disabled: An Open-Label Retrospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Differential effects of topiramate on prefrontal glutamatergic transmission when combined with raclopride or clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Exploration of dimensions of psychopathology in neuroleptic-naïve patients with recent-onset schizophrenia/schizophreniform disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Topiramate-induced psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Neurocognitive impairment across the lifespan in schizophrenia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

The effects of adjunctive topiramate on cognitive function in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Topiramate effect in catatonia: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Topiramate for refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Glutamate receptor dysfunction and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Topiramate-induced psychosis in two members of the one family: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Phenotype of schizophrenia: a review and formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Effects of topiramate on cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

Excitatory amino acid receptors in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548

The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881110372548